PARATHYROID HORMONE (PTH) A new class of osteoporosis treatments called bone formation agents Parathyroid hormone analogues belong to a class of osteoporosis medications which can promote bone growth. In Canada, […]

A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition […]

Osteoporosis does not cause pain. It is a broken bone (fracture) caused by the disease that may cause pain. In fact, osteoporosis has been called “the silent thief” because you […]

A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition […]

Facts & Stats Learn more about osteoporosis and related fractures Osteoporosis is a disease characterized by low bone mass and deterioration of bone tissue which can lead to increased risk […]

Dr. Adrian Lau, Dr. Rowena Ridout, Dr. Claudia Gagnon, Dr. Zahra Bardai, Dr. Emma Billington and Dr. Wendy Ward. Recommendations from Osteoporosis Canada Rapid Response Team. LeBoff and colleagues (1) […]

In 15 of the studies the mean baseline vitamin D level was over 50 nmol/l which is higher than values seen in a significant number of Canadian men and women […]

Living with osteoporosis is a unique journey for each of us. For those with mild osteoporosis there may be little impact on how you live – while for others with […]

Latest News Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis. May 31, 2024 Health Canada has provided authorization to market Jubbonti® (denosumab […]